Immune‐modified Glasgow prognostic score: A new prognostic marker for head and neck cancer

Immune‐modified Glasgow prognostic score: A new prognostic marker for head and neck cancer

Background The modified Glasgow prognostic score (mGPS) includes C‐reactive protein and serum albumin levels and is a useful prognostic tool for malignant tumors. The immune system affects cancer progression and recurrence and treatment response. We hypothesized that increasing the lymphocyte count...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Head & neck 2022-11, Vol.44 (11), p.2555-2563
Hauptverfasser: Terazawa, Kosuke, Ohashi, Toshimitsu, Shibata, Hirofumi, Ishihara, Takuma, Ogawa, Takenori
Format: Artikel
Sprache:eng
Schlagworte:
Cell number
Glasgow prognostic score
Head & neck cancer
Head and neck carcinoma
head and neck squamous cell carcinoma
immune status
Immune system
Lymphocytes
Patients
prognostic factors
Reclassification
Squamous cell carcinoma
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The modified Glasgow prognostic score (mGPS) includes C‐reactive protein and serum albumin levels and is a useful prognostic tool for malignant tumors. The immune system affects cancer progression and recurrence and treatment response. We hypothesized that increasing the lymphocyte count improves mGPS, and we created a new prognostic marker termed immune‐mGPS (imGPS). Methods This study included 461 patients with head and neck squamous cell carcinoma (HNSCC). The imGPS was calculated as the conventional mGPS with one additional point for a low lymphocyte count (
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.27170